PriceTargets.com logo

LON:DPH - Dechra Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 4,180
  • Forecasted Upside: -17.96 %
  • Number of Analysts: 2
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 5,095 As of 10/22/2021 05:45 PM ET
▼ -45 (-0.88%)

This chart shows the closing price for DPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dechra Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DPH

Analyst Price Target is GBX 4,180
▼ -17.96% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Dechra Pharmaceuticals in the last 3 months. The average price target is GBX 4,180, with a high forecast of GBX 4,400 and a low forecast of GBX 3,960. The average price target represents a -17.96% upside from the last price of GBX 5,095.

This chart shows the closing price for DPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 investment analysts is to hold stock in Dechra Pharmaceuticals. This rating has held steady since June 2021, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/22/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/7/2021Liberum CapitalBoost Price TargetSellGBX 3,110 ➝ GBX 3,960
6/9/2021Royal Bank of CanadaBoost Price TargetSector PerformGBX 3,600 ➝ GBX 4,400
3/11/2021Royal Bank of CanadaBoost Price TargetSector PerformGBX 3,450 ➝ GBX 3,600
7/22/2020Jefferies Financial GroupBoost Price TargetBuyGBX 3,185 ➝ GBX 3,515
6/5/2020JPMorgan Chase & Co.Lower Price TargetOverweightGBX 3,300 ➝ GBX 3,200
6/4/2020Royal Bank of CanadaLower Price TargetSector PerformerGBX 2,560 ➝ GBX 2,510
4/24/2020HSBCBoost Price TargetHoldGBX 3,020 ➝ GBX 3,085
3/20/2020Royal Bank of CanadaBoost Price TargetSector PerformerGBX 2,530 ➝ GBX 2,560
3/13/2020Royal Bank of CanadaBoost Price TargetSector PerformerGBX 2,500 ➝ GBX 2,530
2/25/2020JPMorgan Chase & Co.Boost Price TargetOverweightGBX 3,200 ➝ GBX 3,300
1/21/2020Jefferies Financial GroupDowngradeHoldGBX 3,090 ➝ GBX 2,930
1/6/2020JPMorgan Chase & Co.Lower Price TargetOverweightGBX 3,500 ➝ GBX 3,200
12/2/2019HSBCBoost Price TargetHoldGBX 2,915 ➝ GBX 2,950
9/4/2019JPMorgan Chase & Co.Boost Price TargetOverweightGBX 3,000 ➝ GBX 3,500
9/2/2019Royal Bank of CanadaBoost Price TargetSector PerformGBX 2,100 ➝ GBX 2,500
3/25/2019Jefferies Financial GroupBoost Price TargetBuyGBX 2,466 ➝ GBX 2,805
3/25/2019JPMorgan Chase & Co.Initiated CoverageOverweightGBX 3,000
3/11/2019HSBCLower Price TargetBuyGBX 2,770 ➝ GBX 2,700
2/12/2019HSBCInitiated CoverageBuyGBX 2,770
11/23/2018Royal Bank of CanadaLower Price TargetSector PerformerGBX 2,400 ➝ GBX 2,100
9/3/2018Numis SecuritiesDowngradeHold
7/10/2018Numis SecuritiesBoost Price TargetAddGBX 2,640 ➝ GBX 2,950
2/26/2018Royal Bank of CanadaReiterated RatingSector performGBX 2,400
2/26/2018Numis SecuritiesReiterated RatingAddGBX 2,640
2/2/2018Numis SecuritiesReiterated RatingAddGBX 2,640
2/1/2018Royal Bank of CanadaDowngradeSector PerformerGBX 2,200 ➝ GBX 2,400
1/30/2018Jefferies Financial GroupUpgradeBuyGBX 2,221 ➝ GBX 2,631
1/18/2018Numis SecuritiesReiterated RatingAddGBX 2,260
1/17/2018Jefferies Financial GroupReiterated RatingHoldGBX 2,221
9/5/2017Jefferies Financial GroupBoost Price TargetHoldGBX 1,565 ➝ GBX 1,868
7/11/2017Stifel NicolausReiterated RatingHoldGBX 1,550
7/6/2017InvestecReiterated RatingBuyGBX 1,840
7/6/2017N+1 SingerReiterated RatingBuyGBX 1,666
7/6/2017Numis SecuritiesReiterated RatingAddGBX 1,890
4/20/2017Panmure GordonReiterated RatingUnder Review
4/4/2017Numis SecuritiesBoost Price TargetAddGBX 1,700 ➝ GBX 1,890
4/4/2017Stifel NicolausBoost Price TargetHoldGBX 1,440 ➝ GBX 1,550
3/14/2017Royal Bank of CanadaBoost Price TargetOutperformGBX 1,630 ➝ GBX 1,890
3/1/2017Jefferies Financial GroupBoost Price TargetHoldGBX 1,320 ➝ GBX 1,565
2/27/2017N+1 SingerReiterated RatingBuyGBX 1,600
2/27/2017Numis SecuritiesReiterated RatingAddGBX 1,700
2/24/2017FinnCapReiterated RatingUnder Review
1/26/2017Panmure GordonReiterated RatingUnder Review
1/17/2017Numis SecuritiesReiterated RatingAddGBX 1,520
1/17/2017Panmure GordonReiterated RatingUnder Review
12/15/2016Jefferies Financial GroupBoost Price TargetHoldGBX 1,295 ➝ GBX 1,320
11/29/2016FinnCapReiterated RatingUnder Review
10/27/2016Numis SecuritiesReiterated RatingAddGBX 1,520
(Data available from 10/22/2016 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2021

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Dechra Pharmaceuticals logo
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians worldwide. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, and critical care products for dogs and cats; water soluble antibiotics, poultry vaccines, and pain management for poultry, pigs, and cattle; and lameness and pain management products for horses and ponies. It also provides pet nutrition products for supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases. In addition, the company distributes veterinary pharmaceuticals and equipment; offers financial services; markets pet diets; and develops, regulates, manufactures, and markets crop protection. It markets its products through wholesaler and distributor networks. Dechra Pharmaceuticals PLC was incorporated in 1997 and is headquartered in Northwich, the United Kingdom.
Read More

Today's Range

Now: GBX 5,095
Low: 5,040
High: 5,180

50 Day Range

MA: GBX 5,017.61
Low: 4,488
High: 5,405

52 Week Range

Now: GBX 5,095
Low: 3,132
High: 5,525

Volume

172,956 shs

Average Volume

226,482 shs

Market Capitalization

£5.52 billion

P/E Ratio

99.90

Dividend Yield

0.81%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dechra Pharmaceuticals?

The following Wall Street research analysts have issued reports on Dechra Pharmaceuticals in the last year: Liberum Capital, and Royal Bank of Canada.
View the latest analyst ratings for DPH.

What is the current price target for Dechra Pharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for Dechra Pharmaceuticals in the last year. Their average twelve-month price target is GBX 4,180, suggesting a possible downside of 18.0%. Royal Bank of Canada has the highest price target set, predicting DPH will reach GBX 4,400 in the next twelve months. Liberum Capital has the lowest price target set, forecasting a price of GBX 3,960 for Dechra Pharmaceuticals in the next year.
View the latest price targets for DPH.

What is the current consensus analyst rating for Dechra Pharmaceuticals?

Dechra Pharmaceuticals currently has 1 sell rating and 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DPH, but not buy more shares or sell existing shares.
View the latest ratings for DPH.

How do I contact Dechra Pharmaceuticals' investor relations team?

Dechra Pharmaceuticals' physical mailing address is 24 Cheshire Business Park Cheshire Avenue, NORTHWICH, CW9 7UA, United Kingdom. The company's listed phone number is +44-1606-814730. The official website for Dechra Pharmaceuticals is www.dechra.com.